Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Clinical trial NCT03779191 · COMPLETED

Trial details

NCT number: NCT03779191
Sponsor: Instituto Nacional de Cancerologia de Mexico
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

ALK Gene Rearrangement Positive Non-Squamous Non-Small Cell Neoplasm of Lung

Start date: 2020-04-08
Primary completion: 2022-08-01
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.